Mitsubishi Tanabe announced that phase I of its antibody-drug complex MT-8633 against solid cancer will be carried out by Open Innovation Partners, a Tokyo-based venture. It is believed that this move is meant to raise development speed.
Tanabe-Mitsubishi Pharma news release, February 14, 2019
Tanabe Mitsubishi turns product development over to venture company